Who
Peter T. Slover
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Contineum Therapeutics; Chief Financial Officer, Sophiris Bio; VP, Finance and Operations, Anadys Pharmaceuticals.
In numbers
- Trades disclosed
- 16
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 18 Aug 2009
- Last trade
- 30 Jan 2026
- Last filed
- 30 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 30 Jan 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —192,000 at $0.00 | filing |
| 30 Jan 2026filed 30 Jan 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —192,000 at $0.00 | filing |
| 31 Jan 2025filed 31 Jan 2025 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Dec 2019filed 23 Dec 2019 | Sophiris Biooption or derivative | SEC FORM 4 Code A | $37K103,000 at $0.36 | filing |
| 31 Dec 2018filed 3 Jan 2019 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —205,667 at $0.00 | filing |
| 6 Dec 2017filed 8 Dec 2017 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —12,768 at $0.00 | filing |
| 7 Dec 2016filed 9 Dec 2016 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —154,000 at $0.00 | filing |
| 27 May 2016filed 1 Jun 2016 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —103,467 at $0.00 | filing |
| 5 Feb 2015filed 6 Feb 2015 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —37,058 at $0.00 | filing |
| 25 Oct 2013filed 29 Oct 2013 | Sophiris Biooption or derivative | SEC FORM 4 Code A | —147,727 at $0.00 | filing |
| 20 Aug 2013filed 20 Aug 2013 | Sophiris Bio | SEC FORM 4 Bought | $20K4,680 at $4.25 | filing |
| 20 Jan 2011filed 24 Jan 2011 | Anadys Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Dec 2010filed 15 Dec 2010 | Anadys Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —51,750 at $0.00 | filing |
| 3 Dec 2009filed 7 Dec 2009 | Anadys Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —53,086 at $0.00 | filing |
| 18 Aug 2009filed 20 Aug 2009 | Anadys Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.